Citations

Clear

415 citation(s) found for "Snyder, D".

Comparable risk of Barrett’s esophagus with dysplasia between peroral endoscopic myotomy (POEM) and Heller’s myotomy in achalasia: A propensity-matched analysis
Codipilly, Don C. , Snyder, Douglas K. , Alexander, Jeffrey A. , Ravi, K, Perananthan, Varan , Mohamed, Mouhand , Snyder, D, Leggett, Cadman L. , Ravi, K

Mayo Clinic

Endoscopy | March 27, 2025 | Volume: 57 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1805606 Get It

Targeting senescence in Amyotrophic Lateral Sclerosis: senolytic treatment improves neuromuscular function and preserves cortical excitability in a TDP-43Q331K mouse model.
Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Kick, Grace Robinson , Wang, Meifang , Snyder, Harper K., Moore, Peter J., Darvishi, Fereshteh B. , Dashtmian, Anna R. , Ayyagari, Sindhuja N. , Rich, Kelly , Arnold, W. David, Zhu, Yi , Viteri*, Jose A., Kerr*, Nathan R., Brennan*, Charles D., Ketabforoush, Arsh Haj Mohamad Ebrahim , Snyder, Harper K., Moore, Peter J., Zhu, Yi , Arnold, W. David

Mayo Clinic

No container title available | March 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6081213/v1 | PMID 40196013 Get It

Abstract Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive motor neuron degeneration in the primary motor cortex (PMC) and spinal cord. Aging is a key factor in ALS onset and progression, with evidence suggesting that biological aging—a process involving cellular decline— far outpaces chronological aging in ALS. This promotes senescent cell accumulation—marked by irreversible cell-cycle arrest, impaired apoptosis, and chronic inflammation—disrupting tissue homeostasis and impairing neuronal support functions. Thus, targeting senescence presents a novel therapeutic strategy for ALS. Here, we investigated the senolytic combination Dasatinib and Quercetin (D&Q) in TDP-43 Q331K ALS mice. D&Q improved neuromuscular function and reduced plasma neurofilament light chain, a biomarker of axonal damage. The most pronounced improvement was the improved cortical excitability, accompanied by reductions in senescence and TDP-43 in the PMC. These findings highlight the potential of senolytics to mitigate ALS-related dysfunction, supporting their viability as a therapeutic strategy. *Jose A. Viteriab, Nathan R. Kerrab, and Charles D. Brennana are co-first authors.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus
Cohen, Elisabeth J. , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Warner, David B., Lu, Ying , Twi-Yeboah, Alberta , Kim, Jiyu , Lopez-Jimenez, Carlos, Laury, Sarah, Jeng, Bennie H., Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Keenan, Jeremy, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Sugar, Alan , Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Harris, David J. , Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad Fitri , Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, María José , Barron, Bruce J., Hindman, Holly B. , Wise, R., Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, Ann M, Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John E., Ingraham, Herbert J., Guibord, Nathalie M., Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., FORSTOT, S. LANCE, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Ashe, S, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, M. Christopher , Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Robert, Marie‐Claude , Rullo, Jacob, Johnson, Davin , Mah, Dean, Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly , Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Meyer, Jay J. , Niederer, Rachael L. , Colby, Kathryn , McLeod, Stephen D. , Melia, Michele , Sugar, Elizabeth A. , Taylor, Carol R., Nagel, Maria A. , Lass, Jonathan H. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Warner, David B., Lu, Ying, Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Hamrah, Pedram , Lee, Hyunjoo, Weikert, Mitchell P. , Hood, Christopher T. , Woodward, Maria A. , Shtein, Roni Mintz , Zaffos, Joshua, Prescott, Christina R. , Haberman, Ilyse D. , Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Amir, Ahmad, Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Barron, Bruce, Wise, Ronald, Shieh, Christine , Thorne, George, Renucci, A., Sivaraman, Kavitha, Affeldt, John, Guibord, Nathalie M, Lin, Amy , Patel, Ravi, Asbell, Penny A. , Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Yung, C.–W., Lin, Charles C. , Vyas, Neil M, Oates, Dale, Veena, Mathew, Goshe, Jeffrey M. , Sharma, Vikas , Miller, Darby D. , Ma, Jeffrey H, Dupps, William Joseph

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 269

10.1001/jamaophthalmol.2024.6114 | PMID 40048183 Get It

Importance High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (<60 years vs ≥60 years) and disease duration (<6 months vs ≥6 months). Interventions A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study
Warner, David, Jeng, Bennie H., Kim, Jiyu , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Meyer, Jay J. , Lu, Ying , Twi-Yeboah, Alberta , Lopez-Jimenez, Carlos, Laury, Sarah, Cohen, Elisabeth J. , Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Hood, Christopher , Sugar, Alan M., Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad, Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, M.L. , Barron, Bruce, Hindman, Holly B. , Wise, Ronald E. , Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, A., Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John, Ingraham, Herbert J., Guibord, Nathalie M, Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., Forstot, S. Lance, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Patel, Ravi , Ashe, Sanda, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, Michael A., Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Rullo, Jacob, Johnson, Davin , Mah, Dean, Benson, Matthew , Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Lin, Charles C. , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly, Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Sharma, Vikas, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Niederer, Rachael L. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Perez-Quinones, Victor L, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Edmund, Tsui, Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Keenan, Jeremy David , Hamrah, Pedram , Lee, Hyunjoo, Barbato, John D, Weikert, Mitchell P. , Hood, Christopher, Woodward, Maria A. , Sugar, Alan, Shtein, Roni Mintz , Prescott, Christina R. , Haberman, Ilyse D. , Schrack, Katie E, Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Shieh, Christine , Thorne, George, Sivaraman, Kavitha, Lin, Amy , Repine, Karen, Asbell, Penny A. , Ashe, S, Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Hassonlou, Mojgan, Yung, C.–W., Svanda, Kerri, Keppol, Stacy, Vyas, Neil M, McHam, Lisa, Veena, Mathew, Goshe, Jeffrey M. , Miller, Darby D. , Ma, Jeffrey H

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 277

10.1001/jamaophthalmol.2024.6113 | PMID 40048191 Get It

Importance Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. Objective To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). Design, Setting, and Participants Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. Intervention Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. Main Outcomes and Measures Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. Results Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, −20.8% to 25.8%]; P >.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months ( P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, −3.39 months [95% CI, −6.73 to −0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). Conclusions and Relevance One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Commentary on Hiding in Plain Sight: Protein Electrophoresis Profile Inconsistent with Patient’s Diagnosis
Snyder, Melissa R.

Mayo Clinic

Clinical Chemistry | February 3, 2025 | Volume: 71 | Issue: 2 | Pages: 253-253

10.1093/clinchem/hvae162 | PMID 39899478 Get It

Abstract A012: Divergent impacts of DNMT3A and TET2 mutant clonal hematopoiesis on COVID-19 related outcomes
Lasho, Terra, Geyer, Susan M. , Finke, Christy M. , Mangaonkar, Abhishek A. , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik, Harrington, Jonathan J. , Snyder, Melissa R. , Patnaik, Mrinal M. , Fernandez, Jenna , Ismail, Wazim Mohammed , Binder, Moritz , Mazzone, Amelia , Lee, Jeong‐Heon , Wang, Liguo , Munankarmy, Amik , Robertson, Keith D. , Gaspar‐Maia, Alexandre

Mayo Clinic

Cancer Research | February 1, 2025 | Volume: 85 | Issue: 3_Supplement | Pages: A012-A012

10.1158/1538-7445.dnamethylation-a012 Get It

Abstract Background: DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposed epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for hematological neoplasms. In this study, we make use of a natural inflammatory response occurring during COVID-19 to define the impact of these mutations on inflammation and outcomes. Methods: A cohort of 243 community-based patients (Olmsted County, MN) with COVID-19 were identified. CH status was determined on PBMC using error corrected sequencing (lower detection limit 0.5% VAF). In a subset of patients, we use multi-omics interrogation of the genome, transcriptome, and epigenome at single cell (sc) resolution along with DNA methylation, in PBMC, from patients with COVID-19 and CH. Results: We detected 97 CH mutations in 72 (29.6%) of 243 patients with COVID-19. The most frequent being DNMT3A (n=30, 30%) and TET2 (n=26, 28%). The presence of CH negatively impacted overall survival when restricted to TET2 and DNMT3A mutations. However, only DNMT3Amt CH retained age and comorbidity independent prognostication (HR 2.84, p = 0.022). We then assessed for changes in DNA methylation using Illumina MethylationEPIC array on patients with COVID-19 and DNMT3A (n=3) or TET2mt (n=4) CH. Site specific DNA methylation changes revealed significant loss of methylation in DNMT3Amt CH in comparison to TET2mt patients, with 10,944 hypomethylated and 1,160 hypermethylated sites. We found that actively transcribed states (Tx, TxWk) were more commonly hypomethylated in DNMT3Amt CH while enhancers (Enh) and promoters (TssA, TssAFlnk) were more commonly hypomethylated in TET2mt CH. We then conducted scDNA-seq in DNMT3Amt (n=3) and TET2mt (n=1) CH in COVID-19 and observed that while in TET2mt CH, mutations were largely restricted to classical and intermediate monocytes, in DNMT3Amt CH, mutations were seen in myeloid and lymphoid lineage cells. We performed scRNA-seq on patients with COVID-19 and DNMT3A (n=3) or TET2mt (n=6) CH. Differential gene expression analysis identified 1,569 upregulated genes in DNMT3Amt patients and 205 downregulated. Pathway analysis demonstrated an upregulation of genes involved in T cell survival, function, and inflammation in DNMT3Amt patients compared to TET2mt patients with a significant overexpression of GIMAP1, GIMAP4, IRF2, IL32 in multiple cell types. We correlated transcriptomic changes with chromatin accessibility using the 10X Genomics Multiome platform to profile both gene expression and open chromatin from the same samples. Analysis of global distribution of cut sites and differentially accessible peaks showed increased chromatin accessibility in DNMT3Amt CH, especially CD4+ T lymphocytes and NK cells. Conclusion: We demonstrate an age, sex, and comorbidity-independent adverse impact on mortality associated with DNMT3Amt CH in the context of COVID-19 and highlight transcriptomic and epigenetic differences between DNMT3A and TET2mt CH, with single cell resolution. Citation Format: Jenna A Fernandez, Wazim Mohammed Ismail, Moritz Binder, Terra Lasho, Susan M. Geyer, Amelia Mazzone, Christy M. Finke, Abhishek Mangaonkar, Jeong-Heon Lee, Liguo Wang, Vernadette A. Simon, Fariborz Rakhshan Rohakthar, Amik Munankarmy, Jonathan J. Harrington, Melissa R. Snyder, Keith D. Robertson, Alexandre Gaspar-Maia, Mrinal Patnaik. Divergent impacts of DNMT3A and TET2 mutant clonal hematopoiesis on COVID-19 related outcomes [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Methylation, Clonal Hematopoiesis, and Cancer; 2025 Feb 1-4; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2025;85(3 Suppl):Abstract nr A012.
Depressive Symptoms and Amyloid Pathology
Oomens, Julie Elisabeth , Engelborghs, Sebastiaan , Arnim, Christine A. F. Von , Boada, Merçé , Didic, Mira , Dubois, Bruno, Fröhlich, Lutz, Gill, Kiran Dip, Grimmer, Timo, Hildebrandt, Helmut , Itoh, Yoshiaki , Lee, Dong Young , Lleó, Alberto, Meyer, Philipp T. , Kapaki, Elisabeth, Pardini, Matteo , Popp, Julius , Rami, Lorena , Reiman, Eric M. , Rinne, Juha O. , Sánchez‐Juan, Pascual, Sarazin, Marie , Scarmeas, Nikolaos , Villeneuve, Sylvia , Wallin, Anders, Vos, Stephanie J. B. , Jansen, Willemijn J. , group, Amyloid Biomarker Study, Altomare, Daniele , Baldeiras, Inês , Blennow, Kaj, Braber, Anouk den , Cerman, Jiří , Chipi, Elena , Eckerström, Marie , Ekblad, Laura L. , Förster, Stefan , Guedj, Éric , Hausner, Lucrezia , Huey, Edward D. , Jiménez‐Bonilla, J., Johnson, Keith A. , Juaristi, Arantxa, Kern, Silke , Kirsebom, Bjørn‐Eivind , Landau, Susan , Legdeur, Nienke , Guerra, Jorge J. Llibre, Maserejian, Nancy N., Marquié, Marta , Minatani, Shinobu, Olivieri, Pauline , Perrin, Richard J., Peters, Oliver , Prabhakar, Sudesh, Ramakers, Inez H., Rodríguez‐Rodríguez, Eloy , Ruiz, Agustín, Rüther, E., Selnes, Per , Spiru, Luiza , Takeda, Akitoshi , Teichmann, Marc , Thompson, Loisa I., Vogelgsangs, Jonathan, Wallin, Åsa K., Zettergren, Anna , Frisoni, Giovanni B. , Boada, Merce , Oomens, Julie E , Bottlaender, Michel , Wiels, Wietse A. , Baeken, Chris , Dubois, Bruno , Fladby, Tormod , Flier, Wiesje M. van der , Frisoni, Giovanni B. , Fröhlich, Lutz, Grimmer, Timo , Hort, Jakub , Iwatsubo, Takeshi , Klimkowicz‐Mrowiec, Aleksandra , Lleó, Alberto , Martínez‐Lage, Pablo , Mendonça, Alexandre de , Parchi, Piero , Parnetti, Lucilla , Rodrigue, Karen M. , Santana, Isabel , Skoog, Ingmar , Snyder, Peter J. , Sperling, Reisa Anne , Wiltfang, Jens , Zetterberg, Henrik , Ossenkoppele, Rik , Verhey, Frans R.J. , Visser, Pieter Jelle , Alcolea, Daniel , Baiardi, Simone , Bateman, Randall J. , Blennow, Kaj , Buchem, Mark A. van , Byun, Min Soo , Chen, Kewei , Day, Gregory S. , Drzezga, Alexander E. , Epelbaum, Stéphane , Fortea, Juan , Freund‐Levi, Yvonne , Frings, Lars , Hellwig, Sabine , Kandimalla, Ramesh , Paraskevas, George P. , Kornhuber, Johannes , Lagarde, Julien , Morbelli, Silvia , Mroczko, Barbara , Ntanasi, Eva , Oliveira, Catarina Resende , Olivieri, Pauline , Orellana, Adelina , Ruiz, Agustı́n , Silva, Dina , Soininen, Hilkka S. , Tijms, Betty M. , Teunissen, Charlotte E. , Vöglein, Jonathan , Waldemar, Gunhild , Yannakoulia, Mary , Yi, Dahyun

Mayo Clinic

JAMA Psychiatry | January 22, 2025 | Volume: 82 | Issue: 3 | Pages: 296

10.1001/jamapsychiatry.2024.4305 | PMID 39841452 Get It

Importance Depressive symptoms are associated with cognitive decline in older individuals. Uncertainty about underlying mechanisms hampers diagnostic and therapeutic efforts. This large-scale study aimed to elucidate the association between depressive symptoms and amyloid pathology. Objective To examine the association between depressive symptoms and amyloid pathology and its dependency on age, sex, education, and APOE genotype in older individuals without dementia. Design, Setting, and Participants Cross-sectional analyses were performed using data from the Amyloid Biomarker Study data pooling initiative. Data from 49 research, population-based, and memory clinic studies were pooled and harmonized. The Amyloid Biomarker Study has been collecting data since 2012 and data collection is ongoing. At the time of analysis, 95 centers were included in the Amyloid Biomarker Study. The study included 9746 individuals with normal cognition (NC) and 3023 participants with mild cognitive impairment (MCI) aged between 34 and 100 years for whom data on amyloid biomarkers, presence of depressive symptoms, and age were available. Data were analyzed from December 2022 to February 2024. Main Outcomes and Measures Amyloid-β1-42 levels in cerebrospinal fluid or amyloid positron emission tomography scans were used to determine presence or absence of amyloid pathology. Presence of depressive symptoms was determined on the basis of validated depression rating scale scores, evidence of a current clinical diagnosis of depression, or self-reported depressive symptoms. Results In individuals with NC (mean [SD] age, 68.6 [8.9] years; 5664 [58.2%] female; 3002 [34.0%] APOE ε4 carriers; 937 [9.6%] had depressive symptoms; 2648 [27.2%] had amyloid pathology), the presence of depressive symptoms was not associated with amyloid pathology (odds ratio [OR], 1.13; 95% CI, 0.90-1.40; P = .29). In individuals with MCI (mean [SD] age, 70.2 [8.7] years; 1481 [49.0%] female; 1046 [44.8%] APOE ε4 carriers; 824 [27.3%] had depressive symptoms; 1668 [55.8%] had amyloid pathology), the presence of depressive symptoms was associated with a lower likelihood of amyloid pathology (OR, 0.73; 95% CI 0.61-0.89; P = .001). When considering subgroup effects, in individuals with NC, the presence of depressive symptoms was associated with a higher frequency of amyloid pathology in APOE ε4 noncarriers (mean difference, 5.0%; 95% CI 1.0-9.0; P = .02) but not in APOE ε4 carriers. This was not the case in individuals with MCI. Conclusions and Relevance Depressive symptoms were not consistently associated with a higher frequency of amyloid pathology in participants with NC and were associated with a lower likelihood of amyloid pathology in participants with MCI. These findings were not influenced by age, sex, or education level. Mechanisms other than amyloid accumulation may commonly underlie depressive symptoms in late life.
Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease
Kornak, John , Staffaroni, Adam M. , Cadwallader, Claire J. , Lago, Argentina Lario , Webb, Julia D, Chen, Coty , Rascovsky, Katya, Miyagawa, Toji , Ramos, Eliana Marisa , Masdeu, Joseph C. , Pressman, Peter , Rademakers, Rosa , Kremers, Walter K. , Darby, Ryan, Pascual, Belén , Ghoshal, Nupur , Mackenzie, Ian R. , Li, Jingyao , Hall, Jacob , Yutsis, Maya, Litvan, Irene , Henderson, Victor W. , Sivasankaran, Rajeev , Worringer, Katie, Domoto-Reilly, Kimiko, Snyder, Allison, Kramer, Joel H. , Heuer, Hilary W. , Forsberg, Leah K. , Rosen, Howard J. , Boxer, Adam L., Domoto‐Reilly, Kimiko , Damme, Philip Van , Casaletto, Kaitlin B , Masdeu, Joseph C , Pascual, Belen , Litvan, Irene , Sivasankaran, Rajeev , Boeve, Brad , Van Damme, Philip , Kremers, Walter K , Domoto-Reilly, Kimiko , Saloner, Rowan , Villeda, Saul , Paolillo, Emily W. , VandeBunte, Anna M. , Pantelyat, Alexander , Tartaglia, Maria Carmela , Bozoki, Andrea C , Younes, Kyan , Lapid, Maria I. , Hsiung, Ging‐Yuek Robin , Worringer, Katie, Loureiro, Joseph , Boeve, Bradley F. , Rojas, Julio C. , Boxer, Adam L.

Mayo Clinic

Brain Communications | January 15, 2025 | Volume: 7 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcae432 | PMID 39816189 Get It

Abstract The largest risk factor for dementia is age. Heterochronic blood exchange studies have uncovered age-related blood factors that demonstrate ‘pro-aging’ or ‘pro-youthful’ effects on the mouse brain. The clinical relevance and combined effects of these factors for humans is unclear. We examined five previously identified brain rejuvenation factors in cerebrospinal fluid of adults with autosomal dominant forms of frontotemporal dementia and sporadic Alzheimer’s disease. Our frontotemporal dementia cohort included 100 observationally followed adults carrying autosomal dominant frontotemporal dementia mutations (Mage = 49.6; 50% female; 43% C9orf72, 24% GRN, 33% MAPT) and 62 non-carriers (Mage = 52.6; 45% female) with cerebrospinal fluid analysed on Somascan, and longitudinal (Mvisits = 3 years, range 1–7 years) neuropsychological and functional assessments and plasma neurofilament light chain. Our Alzheimer’s disease cohort included 35 adults with sporadic Alzheimer’s disease (Mage = 69.4; 60% female) and 56 controls (Mage = 68.8, 50% female) who completed the same cerebrospinal fluid and clinical outcome measures cross-sectionally. Levels of C-C motif chemokine ligand 11, C-C motif chemokine ligand 2, beta-2-micorglobulin, bone gamma-carboxyglutamate protein (aka Osteocalcin) and colony stimulating factor 2 in cerebrospinal fluid were linearly combined into a composite score, with higher values reflecting ‘pro-youthful’ levels. In genetic frontotemporal dementia, higher baseline cerebrospinal fluid rejuvenation proteins predicted slower decline across cognitive, functional, and neurofilament light chain trajectories; estimates were similar across genotypes. In transdiagnostic analyses, higher cerebrospinal fluid rejuvenation proteins associated with better functional, cognitive, and neurofilament light chain outcomes in adults with sporadic Alzheimer’s disease. Proteins with pre-clinical evidence for brain rejuvenation show translational clinical relevance in adults with Alzheimer’s disease and related dementias and warrant further investigation.
Long‐Term Assessment of Career Outcomes among US‐based Participants in a Novel AD/ADRD Clinical Trial Training Program: the IMPACT‐AD Experience
Mastrolorenzo, Margaret D., Sperling, Reisa, Petersen, Ronald C., Aisen, Paul , Snyder, Heather M. , Raman, Rema , Mastrolorenzo, Margaret D., Carrillo, María C. , Petersen, Ronald C. , Grill, Joshua D.

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S8 | Pages: No page available

10.1002/alz.095374 Get It

AbstractBackgroundThe Institute on Methods and Protocols for Advancement of Clinical Trials in Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD) (IMPACT‐AD) is a novel multi‐disciplinary training program funded by the National Institute on Aging (NIA) and the Alzheimer’s Association for individuals seeking expertise in designing and conducting AD/ADRD trials. IMPACT‐AD offers a Professionals Track for investigators in a variety of trial roles and a Fellowship Track for future AD/ADRD clinical trial principal investigators.MethodTo evaluate long‐term training outcomes, alumni‐scholars from the 2020‐2022 courses (n = 109) were surveyed via REDCap in January 2024. Measured constructs encompassed alumni‐scholar retention in AD/ADRD trials, promotions received, project funding, and the status of the protocol developed during the course, including whether it had been funded, conducted, and published (Fellowship Track). Alumni‐scholars rated the extent to which the course facilitated their achievements (not at all, somewhat, very much).ResultOf the 63 (58%) of alumni‐scholars who responded (48% Professional Track, 69% Fellowship Track), 44 (70%) were female. 21 (33%) identified as African American/Black, Asian, Multiracial or of another race; 7 (11%) self‐identified as Hispanic/Latino ethnicity. 5 (8%) identified as LGBTQ+. 12 (19%) indicated being first in their families to attend college.Since program completion, 87% of survey participants maintained a career in ADRD clinical trials. A majority (63%) experienced a promotion or career advancement, with all indicating that IMPACT‐AD “somewhat” or “very much” contributed. Less than half of scholars (43%) had received project funding since IMPACT‐AD, but 74% of those had credited IMPACT‐AD at least somewhat for this achievement. Among the 34 Fellowship Track respondents, 15 (44%) indicated that the trial proposed at IMPACT‐AD had received funding, 14 (41%) reported its completion, and 5 (15%) had published its results. Nearly all respondents (%) reported assuming additional roles and responsibilities within their current title. In total, 92% of surveyed participants reported at least one positive change across all measured categories.ConclusionIMPACT‐AD is effectively fulfilling its goals of training, nurturing, and diversifying a next generation of AD/ADRD trialists.
Impact of race/ethnicity and area deprivation index on Alzheimer’s disease and related disorders biomarkers in the POINTER Cohort
Landau, Susan, Finn, Quentin, Demesie, Yitbarek N, Yu, Melissa , Lovato, Laura, Snyder, Heather M. , Masdeu, Joseph C. , Pavlik, Valory , Toledo, Jon B. , Pascual, Belén , Harrison, Theresa M. , DeCarli, Charles , Vemuri, Prashanthi , Baker, Laura D. , Masdeu, Joseph C

Mayo Clinic

Alzheimer's & Dementia | January 9, 2025 | Volume: 20 | Issue: S2 | Pages: No page available

10.1002/alz.089954 Get It

AbstractBackgroundThere is limited information on biomarker‐defined Alzheimer’s disease (AD) pathology in community‐recruited individuals of diverse racial and ethnic groups. Here, we assessed the association of race/ethnicity with baseline biomarkers and cognitive measures and hypothesized a lower impact of AD pathology in non‐Hispanic White (nHW) participants in the U.S. POINTER study clinical trial, which evaluates the benefits of a multidomain lifestyle intervention on cognition of community‐recruited at‐risk elderly individuals.MethodWe included 879 participants from the U.S. POINTER study enrolled in the imaging substudy (∼50% of participants) who self‐identified as nHW (n=644), African American/Black (AA/B, n=132), Asian (n=29), and Hispanic (n=74). Outcomes measures included global Aβ pathology (18F‐florbetaben), temporal meta‐ROI tau (18F‐MK‐6240), MRI‐measured white matter hyperintensity volume (WMH) volumes, global clinical dementia rating (gCDR), and global, executive, and memory standardized cognitive scores. The nHW participants were selected as reference. Power transformations normalized skewed distributions. Multivariable linear regressions include age, sex, education, Framingham risk score, and area deprivation index (ADI) as covariates.ResultAA/B harbored lower WMHs, and meta‐temporal tau ROI values. In the full model, 0.5 gCDR participants had higher centiloid values, were more likely to be AA/B and Hispanic, and had a greater burden of WMHs. In addition, higher centiloid values were associated with a 0.5 gCDR in all groups except for the AA/B participants. Hispanic, AA/B, and Asian participants had lower cognitive scores than the nHW group. A higher ADI score was associated with lower global and executive cognitive scores but not with WMH volume or Aβ centiloid score.ConclusionThe analyses of the community‐based U.S. POINTER indicate that AA/B individuals present differences in AD and related dementia biomarker values. nHW had higher fully adjusted cognitive scores. These results indicate a significant heterogeneity in the cognitive testing performance and biomarker values of individuals at risk for dementia in the community.